Fig. 1From: Low-dose decitabine priming with intermediate-dose cytarabine followed by umbilical cord blood infusion as consolidation therapy for elderly patients with acute myeloid leukemia: a phase II single-arm studya Leukemia-free survival according to treatment. The 2-year LFS was 60 and 37.5%, respectively, in the UCB and TCG group (p = 0.057). b Overall survival according to treatment. The 2-year OS was 68 and 45.8%, respectively, in the UCB and TCG group (p = 0.046)Back to article page